Fatih M. Uckun, M.D., Ph.D

Fatih M. Uckun, M.D., Ph.D. is a highly accomplished physician-scientist and pharmaceutical executive with extensive experience in oncology, hematology, and drug development. He currently holds several prominent positions in the biopharmaceutical industry.1

Current Roles

• Head of Immuno-Oncology and Chief Medical/Chief Scientific Officer at Ares Pharmaceuticals, LLC (since July 2015)1
• Head of Strategy for Clinical Development and Translational Hematology-Oncology at AresMIT Biomedical Computational Strategies (A.B.C.S) (since January 2017)1

Professional Background

Dr. Uckun has held leadership positions in various pharmaceutical and biotechnology companies, including:

• Chief Medical Officer/Advisor at Oncotelic (May 2022 - February 2023)1
• Executive Vice President, Global Head of Clinical and Medical Affairs, and Chief Medical & Scientific Officer at Reven Pharmaceuticals (June 2020 - March 2022)1
• Consultant and Chief Clinical Advisor at Aptevo Therapeutics Inc (March 2021 - December 2021)1
• Vice President and Clinical Strategy Lead in Oncology-Hematology at Worldwide Clinical Trials (January 2020 - June 2020)1

Expertise and Contributions

Dr. Uckun is recognized for his expertise in:

• Immuno-oncology
• Clinical trial design and execution
• Translational research in hematology and oncology
• Development of innovative therapeutics

He is an Active Member of the American Society for Clinical Investigation (ASCI), an honor society for physician-scientists.2

Awards and Honors

Throughout his career, Dr. Uckun has received numerous awards, including:

• Leukemia Society of America Scholar Award (1989)1
• Stohlman Memorial Scholar Award, Leukemia Society of America (1992)1
• Multiple Annual Merit Awards from The Saban Research Institute (2012-2014)1
• 2018 Academy Prize in Health and Life Sciences from the Turkish Academy of Sciences1

Dr. Uckun's extensive experience and achievements in the field of oncology and hematology make him a prominent figure in the biopharmaceutical industry, particularly in the development of targeted therapeutics and innovative treatment strategies.